Friday, Jul 24, 2026 The claims desk. Receipts included. POWERED BY LENZ ↗
IsThis

HEALTH

The Claim

A cohort study of 382 adults younger than 60 years old, assessed 3 months after a first myocardial infarction and followed for 20 years, found that participants in the highest tertile of interleukin-6 had a 2.70-fold higher risk of heart-failure hospitalization than those in the lowest tertile (hazard ratio 2.70; 95% CI 1.32–5.50).

Verified by Lenz ·

The Short Version

The described study appears real, and the available evidence supports that higher IL-6 levels measured three months after a first myocardial infarction were linked to higher later risk of heart-failure hospitalization in 382 adults under 60. However, the exact figure cited—hazard ratio 2.70 with 95% CI 1.32–5.50—and the stated 20-year follow-up are not directly verified in the provided evidence. The core association is supported; the precise numerical claim is not fully substantiated here.

Caveats

  • The exact hazard ratio, confidence interval, and follow-up length are not directly shown in the provided source excerpts.
  • A broad directional finding should not be treated as proof of the exact quantitative result without the primary study table or full text.
  • One supporting item is non-citable background knowledge rather than an independent primary source.

The Receipts

  1. IL-6 and Cardiovascular Risk: A Narrative Review

    PMC / NIH

  2. Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized With Heart Failure With Preserved Ejection Fraction

    PubMed

  3. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome

    PubMed

  4. [Study on interleukin-6 and long-term prognosis after first myocardial infarction]

    PubMed

  5. Clinical Significance of Interleukin-6 in Heart Failure: Results from the BIOSTAT-CHF study

    European Journal of Heart Failure

  6. Interleukin-6 and Cardiovascular Events in Healthy Adults: The MESA Study

    Journal of the American College of Cardiology: Advances

  7. Systemic Inflammatory Biomarkers (Interleukin-6, High-Sensitivity C-Reactive Protein, and Tumor Necrosis Factor-Alpha) in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis

    MDPI

  8. Interleukin-6 and Cardiovascular Events in a Multiethnic Cohort

    JACC Advances / University of Groningen

  9. Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin: An Analysis From DAPA-HF

    Journal of the American College of Cardiology: Heart Failure

  10. High levels of interleukin-6 are associated with final infarct size and adverse clinical events in ST-elevation myocardial infarction

    Open Heart (BMJ)

+ 16 more sources — see the full list on Lenz

Filed Under

Heart FailureInterleukin-6Myocardial Infarction

More Fact Checks